Classical markers like ER and Ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients: Results from the GEICAM/2002-01 phase II study

Clinical and Translational Oncology

Volumn 14, Issue 6, 2012, Pages 430-436

  Sánchez Rovira, Pedro ^a   Antón, Antonio ^b   Barnadas, Agustí ^c   Velasco, Amalia ^d   Lomas, María ^e   Rodríguez Pinilla, María ^f   Ramírez, José Luis ^g   Ramírez, César ^a   Ríos, María José ^b   Castellá, Eva ^g   García Andrade, Carmen ^h   San Antonio, Belén ⁱ   Carrasco, Eva ⁱ   Palacios, José Luis ^j  

^a Jaen Hospital Complex   (Spain)

^b HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^c Medical Oncology Department   (Spain)

^d HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^e HOSPITAL INFANTA CRISTINA   (Spain)

^f Structural Biology and Biocomputing Programme   (Spain)

^g HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^h HOSPITAL UNIVERSITARIO SANTA CRISTINA   (Spain)

ⁱ ELI LILLY AND COMPANY   (Spain)

^j HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

more..

Author keywords

Adriamycin; Biomarker; Breast cancer; Gemcitabine; Neoadjuvant chemotherapy; Paclitaxel

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERYTHROPOIETIN; ESTROGEN RECEPTOR; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PROGESTERONE RECEPTOR; PROTEIN P53; SURVIVIN; TUMOR MARKER;

ADULT; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; ASTHENIA; BLEEDING; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CARDIOTOXICITY; CATHETER INFECTION; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ERYTHROCYTE CONCENTRATE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; GENOTYPE; HOSPITALIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFECTION; LEUKOPENIA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; MYCOSIS; NAUSEA; NEUTROPENIA; PARTIAL MASTECTOMY; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PNEUMONIA; PREMENOPAUSE; PROTEIN EXPRESSION; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN TOXICITY; THROMBOCYTOPENIA; TUMOR BIOPSY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DOXORUBICIN; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; KI-67 ANTIGEN; MIDDLE AGED; NEOADJUVANT THERAPY; PACLITAXEL; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ESTROGEN;

EID: 84864690168     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-0820-4     Document Type: Article

References (30)

1. Fisher B, Brown A, Mamounas E et al (1997) Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15: 2483-2493
2. Powles TJ, Hickish TF, Makris A et al (1995) Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 13:547-552
3. Van der Hage JA, van de Velde CJ, Julien JP et al (2001) Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19:4224-4237
4. Wolmark N, Wang J, Mamounas E et al (2001) Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 96-102
5. Bear HD, Anderson S, Brown A et al (2003) The effect on tumour response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 21:4165-4174
6. Green MC, Buzdar AU, Smith T et al (2005) Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23:5983-5992
7. Smith IC, Heys SD, Hutcheon AW et al (2002) Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20:1456-1466
8. Coudert BP, Arnould L, Moreau et al (2006) Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for Her2-overexpressing stage II or III breast cancer: results a multicenter Phase II trial. Ann Oncol 17:409-414
9. World Health Organization (1979) The WHO Handbook for Reporting Results of Cancer Treatment. Offset publication No. 48, Geneva, Switzerland
10. Tumour National Cancer Institute (1998) Cancer Therapy Evaluation Program Common Toxicity Criteria, version 2.0. Available at http://ctep.info.nih.gov/ reporting/index.html
11. Kononen J, Bubendorf L, Kallioniemi A et al (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4:844-847
12. Nielsen TO, Hsu FD, Jensen K et al (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10:5367-5374
13. De las Peñas R, Sanchez-Ronco M, Alberola V et al (2006) Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine- treated non-small-cell lung cancer patients. Ann Oncol 17:668-675
14. Sánchez-Rovira P, Jaén A, González E et al (2001) Biweekly gemcitabine, doxorubicin and paclitaxel as first-line treatment in metastatic breast cancer. Final results from a phase II Trial. Oncology (Williston Park) 15:44-47
15. Lebowitz PF, Eng-Wong J, Swain SM et al (2004) A phase II trial of neoadjuvant docetaxel and capecitabine for locally advanced breast cancer. Clin Cancer Res 10:6764-6769
16. Conte PF, Donati S, Gennari A et al (2005) Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study. Br J Cancer 93:406-411
17. Moebus V, Jackisch C, Lueck HJ et al (2010) Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol 28:2874-2880
18. Von Minckwitz G, Raab G, Caputo A et al (2005) Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol 23:2676-2685
19. Urruticoechea A, Smith IE, Dowsett M (2005) Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 23:7212-7220
20. Dowsett M, Ebbs SR, Dixon JM et al (2005) Biomarker changes during neoadjuvant anastrozole, tamoxifen or the combination: influence of hormonal status and Her-2 in breast cancer-a study from the IMPACT trialists. J Clin Oncol 23:2477-2492
21. Altieri DC (2003) Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3:46-54
22. Span PN, Tjan-Heijnen VC, Manders P et al (2006) High survivin predicts a poor response to endocrine therapy, but a good response to chemotherapy in advanced breast cancer. Breast Cancer Res Treat 98:223-230
23. Kuerer HM, Newman LA, Smith TL et al (1999) Clinical course of breast cancer patients with complete pathologic primary tumour and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 17:460-469
24. Stearns V, Gallagher A, Kleer CG et al (2004) A pilot study to establish a clinical model to perform phase II studies of breast cancer chemopreventive agents in women at high risk with biomarkers as surrogate endpoints for activity. Clin Cancer Res 10:8332-8340
25. Schneider J, Lucas R, Sanchez J et al (2000) Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP. Anticancer Res 20:4373-4377
26. Taucher S, Rudas M, Gnant M et al (2003) Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy. Endocr Relat Cancer 10:91-98
27. Chang GC, Hsu SL, Tsai JR et al (2004) Extracellular signal-regulated kinase activation and Bcl-2 downregulation mediate apoptosis after gemcitabine treatment partly via a p53-independent pathway. Eur J Pharmacol 502:169-183
28. Mathieu MC, Rouzier R, Llombart-Cussac A et al (2004) The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer 403:342-351
29. Cristofanilli M, Gonzalez-Angulo A, Sneige N et al (2005) Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 23:41-48
30. Rouzier R, Perou CM, Symmans WF et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678-5685